Biotricity Posts First Operating Profit, Revenue Jumps 16% to $16M
BTCY is trading near its 52-week low of $0.088 (13% above the low) on light trading volume (0.2× avg).
Summary
Biotricity delivered its first operating profit in FY 2026, with revenue climbing 16% to $16M and net loss narrowing sharply to $(3.13M) from $(11.94M). Gross margin expanded to 81%, driven by higher-margin technology fees and lower monitoring costs. This follows the 10-K filed today and the pending 1-for-100 reverse stock split approved in May. The going concern warning from auditors remains a key risk, but the operational turnaround is material for a micro-cap company. The reverse split, if executed, could alter share dynamics significantly.
At the time of this announcement, BTCY was trading at $0.10 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $0.09 to $0.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.